NDLI: Pharmacokinetics, pharmacodynamics, and safety of landiolol hydrochloride in healthy Chinese subjects.

Please wait, while we are loading the content...

Year: 2017 Volume: 67

Year: 2016 Volume: 66

Year: 2015 Volume: 65

Year: 2014 Volume: 64

Year: 2014 Volume: 64 Issue: 12

Year: 2014 Volume: 64 Issue: 11

Year: 2014 Volume: 64 Issue: 10

Year: 2014 Volume: 64 Issue: 9

Year: 2014 Volume: 64 Issue: 8

Year: 2014 Volume: 64 Issue: 7

Year: 2014 Volume: 64 Issue: 6

Year: 2014 Volume: 64 Issue: 5

Year: 2014 Volume: 64 Issue: 4

Year: 2014 Volume: 64 Issue: 3

The relationship between anagliptin concentration showing over 80% inhibition of plasma dipeptidyl peptidase-4 activity and its protective effect against glucagon-like peptide-1 degradation.

Use of lavage fluids in arthroplasty to prevent postoperative infections.

Drug release kinetic analysis and prediction of release data via polymer molecular weight in sustained release diltiazem matrices.

Application of artificial neural networks for optimization of preparation of insulin nanoparticles composed of quaternized aromatic derivatives of chitosan.

Bioequivalence study of two risedronate sodium film-coated tablet formulations in healthy volunteers.

Antidepressant-like property of Jobelyn®, an African unique herbal formulation, in mice.

Pharmacokinetics, pharmacodynamics, and safety of landiolol hydrochloride in healthy Chinese subjects.

Development and in-vitro characterization of fish oil oleogels containing benzoyl peroxide and salicylic acid as keratolytic agents.

Development of validated stability indicating assay method for simultaneous estimation of metformin hydrochloride and vildagliptin by RP-HPLC.

Effect of cyanocobalamin (vitamin B12) in the induction and expression of morphine tolerance and dependence in mice.

Year: 2014 Volume: 64 Issue: 2

Year: 2014 Volume: 64 Issue: 1

Year: 2013 Volume: 63

Pharmacokinetics, pharmacodynamics, and safety of landiolol hydrochloride in healthy Chinese subjects.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Wang, M. Zhang, Q. Hua, W. Zhou, W. Huang, M. Wang, H.
Description	Country affiliation: China Author Affiliation: Wang M ( Clinical Pharmacology Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, China.); Zhang Q ( Clinical Pharmacology Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, China.); Hua W ( Clinical Pharmacology Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, China.); Zhou W ( Clinical Pharmacology Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, China.); Huang M ( Clinical Pharmacology Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, China.); Wang H ( Department of Medicine, Chongqing Pharmaceutical Research Institute Co., Ltd, Chongqing, China.)
Abstract	OBJECTIVE: Landiolol is an ultra-short-acting ß-blocker that appears to be more cardioselective and less toxic than esmolol. The main objective of this study was to investigate the pharmacokinetics, pharmacodynamics, and safety of landiolol hydrochloride in healthy Chinese volunteers. METHODS: We set 2-dose regimen (L and H groups) [L (low): 0.125 mg/kg/min (1 min) loadingâ0.02 mg/kg/min (20 min) continuous, H (high): 0.25 mg/kg/min (1 min) loadingâ0.04 mg/kg/min (20 min) continuous]. 20 healthy subjects of either sex were allocated randomly to the L and H groups (n=10, and 10). Blood samples were collected over 1 h after continuous infusion and were determined using a validated liquid chromatography/mass spectrometry (LC/MS/MS) assay. The safety of landiolol hydrochloride was assessed by adverse events recording, 12-lead ECG findings, physical examination, laboratory testing, and vital signs. RESULTS: The main pharmacokinetic parameters of landiolol hydrochloride in healthy Chinese subjects were as follows: doses of 2 groups (L and H); Cmax of 400±110 and 731±246 ng/mL; C21min of 327±109 and 508±141 ng/mL; Tmax of 10.1±6.5 and 6.2±5.7 min; t1/2 of 4.7±1.6 and 6.5±1.7 min. Landiolol hydrochloride was safe. There were no adverse events in any subject. The heart rates and blood pressures of subjects administered landiolol hydrochloride decreased, but no clinically significant changes were observed. CONCLUSION: The concentration of landiolol hydrochloride rapidly reached steady state levels, and rapidly dissipated after completion of administration. Landiolol hydrochloride appears to have rapid onset and short action.
File Format	HTM / HTML
ISSN	21949379
Issue Number	3
Volume Number	64
e-ISSN	21949387
Journal	Drug Research
Language	English
Publisher	Thieme
Publisher Date	2014-03-01
Publisher Place	Germany
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Adrenergic Beta-antagonists Administration & Dosage Chromatography, Liquid Methods Morpholines Tandem Mass Spectrometry Urea Analogs & Derivatives Pharmacokinetics Pharmacology Adult Asian Continental Ancestry Group Blood Pressure Drug Effects Dose-response Relationship, Drug Electrocardiography Female Heart Rate Humans Male Young Adult Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Medicine Drug Discovery

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in